Immunovant, Inc. (IMVT) FY2026 earnings

Reported results

• Net loss was $97.2 million, or $0.47 per common share, for the three months ended September 30, 2026.
• Non-GAAP net loss was $84.0 million for the three months ended September 30, 2026.
• Research and development expenses were $85.0 million for the three months ended September 30, 2026.
• Non-GAAP R&D expenses were $78.5 million for the three months ended September 30, 2026.
• General and administrative expenses were $19.1 million for the three months ended September 30, 2026.
• Cash and cash equivalents totaled $722.3 million as of September 30, 2026.

Guidance

• The Company expects to report topline data across potentially registrational trials of IMVT-1402 in Graves’ disease (GD) and myasthenia gravis (MG) in calendar year 2027.
• Topline data are expected in calendar year 2028 for the potentially registrational trial of IMVT-1402 in chronic inflammatory demyelinating polyneuropathy (CIDP).
• Cash and cash equivalents of $722.3 million as of September 30, 2026 are expected to provide runway to the potential commercial launch of IMVT-1402 in GD, based on current operating plan.

Price and volatility reaction

The stock moved +15.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +30.5 vol points across the event (constant-maturity series — not the front-week crush).

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.